Clinical Trials Logo
  1. Home
  2. Granulomatosis With Polyangiitis
  3. NCT04871191

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis — SATELITE  

Granulomatosis With Polyangiitis Clinical Trial

Official title:
Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis

Clinical Trial Summary

The purpose of this study is to identify the most promising therapeutic strategy for patients with granulomatosis with polyangiitis and inadequate response to standard of care therapy. It will evaluate the efficacy to induce remission of three different salvage strategies including: a combination of rituximab with addition of a conventional disease-modifying antirheumatic drugs (either methotrexate, azathioprine or mycophenolate mofetil, but preferentially methotrexate); tocilizumab; or abatacept.

Clinical Trial Description

Granulomatosis with polyangiitis (GPA) is an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). Combination of glucocorticoids and either cyclophosphamide or rituximab is the standard of care for remission-induction of new-onset organ-threatening or life-threatening GPA. Few patients fail to respond to both cyclophosphamide and rituximab, but it is not uncommon for patients to have persistent disease activity resulting in inability to taper glucocorticoids, which is also considered refractory disease. The current recommendations for patients with GPA refractory to remission-induction therapy are to switch from cyclophosphamide to rituximab or from rituximab to cyclophosphamide. However, there are no recommendations for the management of patients with inadequate response after both treatments. Treatment with a biologic disease-modifying antirheumatic drugs (DMARD) or a combination of rituximab and a cDMARD are potential treatments options but have not been properly evaluated in such cases. Among biologic DMARD that have been evaluated in AAV, some have shown promising results, including tocilizumab and abatacept. Identifying the most promising therapeutic strategy for patients with GPA and inadequate response to standard of care therapy may improve management of GPA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04871191
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Jonathan London, MD
Phone +33 1 44 64 16 02
Email jlondon@hopital-dcss.org
Status Not yet recruiting
Phase Phase 2
Start date March 2023
Completion date January 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT01731561 - Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Phase 3
Completed NCT01862068 - Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
Completed NCT01750697 - A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Phase 2
Not yet recruiting NCT02126098 - Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis N/A
Terminated NCT01586858 - Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study N/A
Active, not recruiting NCT03919435 - TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Phase 1/Phase 2
Terminated NCT05376319 - PR3-AAV Resilient Remission or PRRR Phase 2
Not yet recruiting NCT05353179 - Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Early Phase 1
Completed NCT02169219 - Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Phase 4
Completed NCT01613599 - An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Active, not recruiting NCT05716334 - Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
Recruiting NCT04944524 - Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Phase 4
Completed NCT03430388 - Yellow Fever Vaccine in Patients With Rheumatic Diseases N/A
Completed NCT03410290 - Journey of Patients With Vasculitis From First Symptom to Diagnosis
Recruiting NCT03482479 - Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Phase 2
Active, not recruiting NCT01940094 - The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach Phase 3
Recruiting NCT01405807 - Alemtuzumab for ANCA Associated Refractory Vasculitis Phase 4
Active, not recruiting NCT01933724 - The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach Phase 3
Completed NCT05703802 - Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
Active, not recruiting NCT03967925 - Rituximab and Belimumab Combination Therapy in PR3 Vasculitis Phase 2